AstraZeneca, J&J Execs Tout Sellas\u2019 GPS\u00a0<\/p>\n
The comments emerged as part of a weekend LinkedIn discussion about the rise of personalized cancer vaccines and their potential to prevent cancer from returning.<\/p>\n
The original\u00a0post<\/a>, by Healthspan AI adviser Stuart Diamond, focused on Moderna and Merck\u2019s personalized mRNA cancer vaccine intismeran, combined with Keytruda, meeting the primary endpoint in a Phase 3 melanoma trial. Michael Anglestein, a senior respiratory biologics sales specialist at AstraZeneca, then turned the conversation to Sellas\u2019 galinpepimut-S (GPS).<\/p>\n \u201cThe REGAL Phase 3 trial for AML is a game changer for CR1 & CR2 patients,\u201d Anglestein said. \u201cThe trial has been going on for 5 1\/2 years with no futility and very few side effects.\u201d Anglestein added that GPS and Sellas\u2019 other clinical candidate, SLS009, would be \u201cgame changers\u201d for AML and potentially other cancers.<\/p>\n Rob Tomko, a medical-device industry executive, agreed. \u201cGoing to be an absolute blockbuster once the results come out,\u201d Tomko said. \u201cI couldn\u2019t agree more!\u201d<\/p>\n A Stocktwits user also\u00a0highlighted<\/a> a LinkedIn comment attributed to Michael Frascello, a product director at Johnson & Johnson, that appears to have since been deleted. \u201cAgree Sellas GPS and REGAL will be a game changer for AML care,\u201d Frascello reportedly said.<\/p>\n When another user asked how much research supported his view, and mentioned shareholder speculation about J&J potentially acquiring Sellas, Frascello said: \u201cThis is based on my own personal research and analysis.\u201d He also added:\u201cI\u2019ve been analyzing SLS for over a year and a half now!\u201d The chatter drew attention as J&J\u00a0targets<\/a> more than $50 billion in oncology sales by 2030 and continues expanding through acquisitions.<\/p>\n Sellas\u2019 Regal Nears Final Trigger<\/p>\n The key catalyst for Sellas is Regal, which has recorded 78 of the 80 events required to trigger its final efficacy analysis. After the 80th event, the company plans to announce the milestone before beginning database lock, review, statistical analysis and unblinding.<\/p>\n Sellas CEO Angelos Stergiou said the company had entered a quiet period, while its team prepares for the database lock and advances regulatory work. Regal will be considered successful if GPS produces a median overall survival of 12.6 months, compared with eight months for the control arm. Positive results could drive a potential biologics license application to the Food and Drug Administration (FDA).<\/p>\n \u201cWe are approaching the pre-specified 80th event in the Phase 3 REGAL trial, marking a critical step toward the final efficacy analysis and, if successful, a potential BLA submission to the FDA,\u201d Stergiou said earlier this month.<\/p>\n How Do Retail Traders Feel About SLS?<\/p>\n On Stocktwits, retail sentiment for SLS declined to \u2018neutral\u2019 from \u2018bullish\u2019 levels a day ago amid a 109% jump in 24-hour message volumes.<\/p>\n One user\u00a0said<\/a>, \u201c$SLS The most meaningful aspect is not their employers\u2014it is that identifiable pharmaceutical professionals consider the public REGAL evidence compelling enough to make unusually confident predictions under their real names…..\u201d<\/p>\n In a retail\u00a0poll<\/a> by another user, 58% of voters expected Sellas to announce Regal\u2019s 80th event this week, while 35% said they did not, based on 60 votes.<\/p>\n SLS stock has surged 588% over the past year.\u00a0<\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n Read Next:\u00a0Why Retail Traders Couldn\u2019t Take Their Eyes Off These Stocks Last Week: NVDA, CRWD, MRVL, CRM, ASTS\u00a0<\/a><\/p>\n![\"sls](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/08\/sls_ss_75a9961812.png\")
SLS sentiment and message volume as of August 30 | Source: Stocktwits<\/p>\n
![\"Follow](\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/){kind=icon}
<\/a><\/p>\n